Compare TARA & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARA | CFBK |
|---|---|---|
| Founded | N/A | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 231.8M |
| IPO Year | 2014 | 2005 |
| Metric | TARA | CFBK |
|---|---|---|
| Price | $3.84 | $34.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $24.40 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 367.3K | 58.1K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 1.23% |
| EPS Growth | ★ 38.25 | 30.58 |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | $31.99 |
| Revenue Next Year | N/A | $9.09 |
| P/E Ratio | ★ N/A | $20.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $22.10 |
| 52 Week High | $7.82 | $36.95 |
| Indicator | TARA | CFBK |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 47.76 |
| Support Level | $3.73 | $32.20 |
| Resistance Level | $4.20 | $36.82 |
| Average True Range (ATR) | 0.15 | 0.85 |
| MACD | -0.01 | -0.31 |
| Stochastic Oscillator | 15.19 | 20.67 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.